Get started
Author

Thomas J. Schuetz

Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
2010 · Philip W. Kantoff, Thomas J. Schuetz, et al. · Journal of Clinical Oncology · 1,002
A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)
2006 · Joseph Muenzer, Muge Gucsavas-Calikoglu, et al. · Molecular Genetics and Metabolism · 219
A Phase I Trial of Pox PSA vaccines (PROSTVAC®-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™) in Patients with Prostate Cancer
2006 · RS DiPaola, M Plante, et al. · Journal of Translational Medicine · 190
PDF
Targeting the DLL/Notch Signaling Pathway in Cancer: Challenges and Advances in Clinical Development
2022 · Weon-Kyoo You, Thomas J. Schuetz, et al. · Molecular Cancer Therapeutics · 85
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers
2017 · David Monteith, Emily C. Collins, et al. · Frontiers in Pharmacology · 67
PDF
Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity
2020 · Ugur Eskiocak, Wilson Guzman, et al. · JCI Insight · 49
PDF
CTX-8573, an Innate-Cell Engager Targeting BCMA, is a Highly Potent Multispecific Antibody for the Treatment of Multiple Myeloma
2019 · Jennifer Watkins-Yoon, Wilson Guzman, et al. · Blood · 39
Randomized, double-blind, vector-controlled study of targeted immunotherapy in patients (pts) with hormone-refractory prostate cancer (HRPC)
2006 · P. W. Kantoff, L. M. Glode, et al. · Journal of Clinical Oncology · 24
Extended survival in second-line pancreatic cancer after therapeutic vaccination
2005 · T. Schuetz, H. L. Kaufman, et al. · Journal of Clinical Oncology · 16
Abstract 4972: Preclinical development of a first-in-class NKp30xBCMA NK cell engager for the treatment of multiple myeloma
2019 · Monia Draghi, Jamie L. Schafer, et al. · Cancer Research · 13
Two phase I studies of prime-boost vaccinations with vaccinia-fowlpox vaccines expressing CEA, MUC-1, and TRICOM costimulatory molecules (B7.1/ICAM-1/LFA-3) in patients with advanced pancreatic cancer
2004 · T. Schuetz, J. Marshall, et al. · Journal of Clinical Oncology · 10
A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity
2024 · Diana I. Albu, Benjamin J. Wolf, et al. · OncoImmunology · 4
Phase 1 study of CTX-471, a novel CD137 agonist antibody, in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies.
2024 · Minal A. Barve, Tanner Michael Johanns, et al. · Journal of Clinical Oncology · 3
PDF
7002 Further analysis of a Phase II randomized controlled trial (RCT) of a poxviral-based PSA targeted immunotherapy in metastatic castration-resistant prostate cancer (mCRPC)
2009 · W.R. Godfrey, B.A. Blumenstein, et al. · European Journal of Cancer Supplements · 3
Abstract 7297: Enhanced efficacy of CTX-471, a CD137 agonist antibody, in models of immune checkpoint failure via simultaneous blockade of neo-angiogenesis
2025 · Amy Daniel Ulumben, Diana I. Albu, et al. · Cancer Research · 1
Trial in progress: A phase 2 study of CTX-009 in adult patients with metastatic colorectal cancer who have received two or three prior systemic chemotherapy regimens.
2023 · Marilyn Fontaine, Sarah Pilgrim, et al. · Journal of Clinical Oncology · 1
Bispecific anti-PD-1/PD-L1 antibody CTX-8371 to promote cellular clustering and PD-1 shedding, antitumor activity and tolerability.
2021 · Diana I. Albu, Yan Qin, et al. · Journal of Clinical Oncology · 1
A novel non-HLA-restricted cellular immune assay for monitoring patient (pt) response to targeted immunotherapeutics
2006 · K. Manson, K. E. Dolan, et al. · Journal of Clinical Oncology · 1
Safety profile of therapeutic pox virus-based vaccines for cancer
2004 · H. L. Kaufman, R. Dipaola, et al. · Journal of Clinical Oncology · 1
Manipulating the local tumor microenvironment with vaccinia virus expressing costimulatory molecules for the treatment of melanoma
2004 · C. S. Hesdorffer, H. Hoerig, et al. · Journal of Clinical Oncology · 1
678 VEGF-dependent cleavage of cell surface PD-1 mediated by CTX-10726, a novel PD-1 x VEGF-A bispecific antibody
2026 · Diana I Albu, Amy Daniel Ulumben, et al. · Journal for ImmunoTherapy of Cancer
PDF
COMPANION-002: A Randomized Phase 2/3 Trial of Tovecimig Plus Paclitaxel versus Paclitaxel Alone as a Second-line Therapy in Patients with Advanced Biliary Tract Cancer
2026 · Nilofer S Azad, Ian Hu, et al. · Journal of Clinical Oncology
Phase 1 dose escalation of CTX-8371, a novel PD-1×PD-L1 bispecific antibody, in patients with advanced malignancies post checkpoint inhibition.
2026 · Judy S. Wang, Jeffery Scott Russell, et al. · Journal of Clinical Oncology
Abstract CT118: A phase 1 study of CTX-8371, a bispecific PD-1/PD-L1 antibody, in patients with advanced malignancies
2025 · Judy Wang, Cesar A. Perez, et al. · Cancer Research
679 Pharmacodynamic and response biomarkers in the monotherapy arm of a phase 1 trial of CTX-471, a novel anti-CD137 agonist antibody
2024 · Kris Sachsenmeier, Niharika Mettu, et al. · Journal for ImmunoTherapy of Cancer
Works count: 26
Citation count: 1,730
H-index: 10
I10-index: 11
Year
Topic
Type